Alderley Park, England (ots/PRNewswire) - - First Patient Enrolled in Pivotal International Randomised, Double-Blind Study of Vandetanib Versus Erlotinib FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca (NYSE:AZN) today announced the start of enrolment into a new Phase III study of the novel ...
Cordis Medizinische Apparate GmbH
Paris (ots/PRNewswire) - - Shipment of First Third-Generation Drug-eluting Stent Starts Cordis Corporation, the world leader in the drug-eluting stent market, announced today the launch of the CYPHER SELECT(TM) Plus Stent. The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific ...
SWIFTWATER, Pennsylvania & LYON, France, September 26 (ots/PRNewswire) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell ...
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MDFY), today announced that it has signed an agreement with AlwaysON, a leading provider of managed IP communications services. This contract will provide the underpinning network infrastructure and telecommunication services for the rollout and delivery of the MedifyRemote application to ...
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden ...
World Federation for Mental Health
Paris (ots/PRNewswire) - - Multi-National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians (PCPs) believe medical school training about depression -- specifically regarding its painful physical symptoms -- needs to be improved, according to findings from a multi-national survey ...
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in ...
Paris (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US) Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years before receiving appropriate treatment and up to half of all ...
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine (NEJM), all of which reaffirmed the safety and efficacy of drug-eluting stents. Commenting on the ...
The Bill & Melinda Gates Foundation
Seattle (ots/PRNewswire) - - Four Grants Support Development of Vaccines and Better Drugs, and Launch of New Medical Journal The Bill & Melinda Gates Foundation today announced four grants totaling US$68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable ...
Copenhagen, Denmark (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated ...
Copenhagen, Denmark (ots/PRNewswire) - - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With Diabetes Gained Less Weight With Exubera Than With Injectable ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - Not for Distribution in the United States The first anti-anaemia treatment produced in a human cell line, DYNEPO(R) (epoetin delta), can effectively control anaemia in patients with chronic kidney disease (CKD[x]) according to two Phase III studies presented for the first time today.(1),(2) Patients with kidney ...
Luxembourg (ots/PRNewswire) - Gemplus International S.A. (Euronext LU0121706294 - GEM and NASDAQ:GEMP), a world leading player in the secure card industry and a subsidiary of Gemalto N.V. (Euronext NL0000400653 - GTO), announces today that it no longer expects to meet its financial performance outlook for 2006. The Company cited market conditions that will remain challenging and uncertainties in the global economic environment. Because of the level of its integration ...
New York (ots/PRNewswire) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only being launched into the German market in May 2006, it has been immediately ...
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS), today received partner approval to release the current forward order book. These figures include all current and forward sales for both the UK and European operations. Medify Solutions Limited is contracted to deliver the MedifyRemote application to the UK and the Italian ...
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS) today issued the latest investors update. The update is available to view on the company's website, www.medifysolutions.com under the latest news section. Company website : www.medifysolutions.com This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results ...
Macclesfield, England (ots/PRNewswire) - - www.novelneuroprotection.com Aims to Increase Understanding of Acute Ischemic Stroke and the Potential Role of Neuroprotection - For Medical Media Only A new resource for the international medical community was launched in September 2006 by AstraZeneca, www.novelneuroprotection.com. This educational site aims to help healthcare professionals understand more about ...
Paris (ots/PRNewswire) - The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI): An International Randomized Evaluation), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated ...
Toronto, Canada (ots/PRNewswire) - - Mobile Access to Clinical Data now Available on BlackBerry Devices Medify Solutions Limited (Pink Sheets - MFYS) today announced that its product portfolio will be available on BlackBerry(R) handsets. The MedifyRemote application allows mobile access to patient notes and clinical systems in real time, helping doctors and nurses to provide better, more efficient and more ...
Sanofi-aventis; Bristol-Myers Squibb
Paris (ots/PRNewswire) - - PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission has granted a new indication for the antiplatelet ...
New York (ots/PRNewswire) - - Heart Disease Patients who Were at a Very High Risk for Having a Second Heart Attack and Took Lipitor 80mg Had a 46 Percent Reduction in the Risk of Experiencing Additional Heart Attacks Compared With Patients Taking Simvastatin - Investigator: 'These data suggest the benefit ...
Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with pramipexole (Sifrol(R)/Mirapexin(R)), ...
Basel, Switzerland (ots/PRNewswire) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re-examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment of pancreatic cancer ...
Hospital Pitie Salpetriere-Institut du coeur
Barcelona, Spain (ots/PRNewswire) - Results of the multinational, prospective, observational RIVIERA registry (Registry on IntraVenous anticoagulation In the Elective and primary Real world of Angioplasty) announced today at the World Congress of Cardiology 2006- joint meeting of the European Society of ...
New York (ots/PRNewswire) - - Lipitor Reduces Risk of Major Cardiovascular Events Such as Heart Attacks in People With Heart Disease and With a Cluster of Other Major Cardiovascular Risk Factors, Often Referred to as Metabolic Syndrome, New Analysis Shows - Heart Disease Patients With Metabolic Syndrome who Took Lipitor 80mg Dose Reduced Their Risk of Major Cardiovascular Events by Nearly 30 ...
Barcelona (ots/PRNewswire) - - Results of the PCI-ExTRACT Sub-Study Results of the PCI-ExTRACT-TIMI 25 study announced today at the World Congress of Cardiology-European Society of Cardiology 2006 in Barcelona, showed that among patients with ST-segment elevation myocardial infarction (STEMI) who ...
Barcelona, Spain (ots/PRNewswire) - - Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a number of clinical benefits to elderly people with chronic heart failure according to the results of a study presented at ...
Edmonton, Alberta (ots/PRNewswire) - - Isotechnika Inc. announced today promising results from its Phase I TAFA93 trials. TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation. mTOR inhibitors are typically used in combination with ...
The Alliance for Better Bone Health
Paris, France (ots/PRNewswire) - - Male Osteoporosis: Neglected and Under Treated PARIS, France, August 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) this week approved Actonel(R) 35mg (risedronate sodium tablets) for 'treatment to increase bone mass in men with osteoporosis'. This follows the positive outcome in July 2006 of the European application for the additional indication of ...